POSITION
Co-Investor
BOARD
None
Exit
Acquired by Ironwood in 2023
VectivBio AG is a late clinical-stage biotechnology company focused on rare conditions with well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. The company is drawing on the expertise of its founders as it continues building a portfolio of rare disease medicines while advancing its lead program for Short Bowel Syndrome (SBS) with Apraglutide which has the potential to be a best-in-class treatment.
Apraglutide program was part of GlyPharma Therapeutic Inc. (a Fund I portfolio company) acquired by Therachon in October 2018.